Pharmacovigilance in seasonal malaria chemoprevention in northern Nigeria
Published:
Resources: Poster
Authors: Jimmy Aiden, Kenneth Maduka, Mujahid Idris, Chrysanthus Dabes, Obinna Emeruwa, Abba Sagagi, Taiwo Ibinaiye, Bello Magaji, Babatunde Fagbemi, Kunle Rotimi, Abimbola Phillips, Olatunde Adesoro, Olusola Oresanya
Pharmacovigilance is well integrated in SMC, yet reporting of suspected adverse medicine reactions is low.
Pharmacovigilance (PV) in seasonal malaria chemoprevention (SMC) involves the identification and reporting of suspected adverse drugs reactions (ADR). Although PV is a core component of SMC, its functionality has not been well evaluated in Nigeria, where about four million eligible children received SMC in 2019. SMC implementation includes a referral and reporting system, used by health facility workers to inform the National Pharmacovigilance Centre, via National Agency for Food and Drug Administration and Control state offices, of SMC-related ADR among communities.
This poster was presented at the 69th annual meeting of the American Society of Tropical Medicine and Hygiene.
